Bridger Management LLC

-

Assets, Funds, Holdings

Home | Sign Up | Log In
New Features
Latest Fund Raises
Related People
Fund Service Providers
Startup & Company Raises
List of Funds
Boston Firms
Boston Hedge Funds
Cornell Alumni Firms
CalPERS Portfolio
NYSCRF Portfolio
User Guide
Regulatory AUM vs AUM
LP Portfolios
Related Firms
Build a Portfolio
Comprehensive Search
Keyboard
Bridger Management LLC
CRD #160738
SEC #801-74245
CIK #0001166309
AUM 485.2 M (2026-03-27)
Employees 8 (62% Investors, 0% Brokers)
Fees
Minimum
Phone212-984-2125
Address90 Park Avenue 40th Fl
New York, NY 10016
Source [IAPD] [EDGAR] [Website] [LinkedIn]
Total AUM ($B)
4.03.22.41.60.80.02010201520212027
Fees and Compensation — Form ADV Part 2A (3/27/2026) [Brochure]
Item 5: Fees and Compensation

Asset-Based and Performance-Based Compensation

The fees and compensation applicable to each of the Funds are set forth in detail in the
corresponding Offering Documents. A brief summary of the fees and compensation applicable to
the Funds is provided below.

We receive from the Swiftcurrent Fund a quarterly management fee (the “Management Fee”),
which ranges from 1.5% to 2.0% per annum of the net asset value of a Fund and is paid from the
assets of the Swiftcurrent Fund quarterly in advance, and an allocable portion of the Management
Fee is deducted from each relevant investor’s account at the beginning of the relevant accounting
period. In the case of an investor admitted to a Fund after the first business day of the relevant
calendar quarter, the Management Fee is pro-rated based on the admission date of such investor.

Effective as of January 1, 2023, Bridger has waived all future Management Fees for the Healthcare
Fund.

Management Fees assessed on investments in pooled investment vehicles by Bridger, its affiliates
their principals, members of the immediate families of such persons or trusts or other entities for
their benefit are reduced or waived entirely.

Generally, a Fund will pay the Management Fee in advance. If the investment management
agreement is terminated before the end of the billing period, Bridger will refund a pro rata portion
of the pre-paid fee to the Fund’s investors.

The Auson Fund is not charged any Management Fees.

An affiliate of Bridger is entitled to an incentive allocation (the “Incentive Allocation”) from the
Swiftcurrent Fund equal to 20% of any net profit allocable to each investor for such fiscal year in
excess of any loss recovery with respect to such investor’s account, adjusted for contributions,
withdrawals and distributions. The Incentive Allocation will be allocated as of the close of each
fiscal year and on any interim redemption or withdrawal of capital by an investor.

Bridger Management, LLC                                                Form ADV Part 2A Brochure

Effective as of January 1, 2023, an affiliate of Bridger waived its entitlement to receive any future
Incentive Allocation from the Healthcare Fund.

Incentive Allocation assessed on investments in pooled investment vehicles by Bridger, its
affiliates, their principals, members of the immediate families of such persons or trusts or other
entities for their benefit are reduced or waived entirely.

The Auson Fund is not subject to any Incentive Allocation.

Other Expenses

The Funds bear their own costs and expenses, such as administrative expenses, investment
expenses (e.g., brokerage commissions and expenses of outsourced trading desks, and interest
expense), fees and expenses of their governing bodies, legal expenses, valuation, accounting
(including without limitation the fees and expenses of any administrator retained for the Funds and
the fees and expenses related to regulatory filings of the Funds, the general partner/managing
member and Bridger that relate to the Funds (including by way of illustration, Form PF)), auditing
and tax preparation expenses, taxes, expenses relating to the offer and sale of interests in the Funds,
expenses relating to the organization of the Funds and extraordinary expenses. To the extent the
Funds invest in exchange traded funds and/or private investment funds, the Funds would be subject
to additional fees and expenses payable by such funds. Costs and expenses common to one or
more Clients are generally paid pro rata by each Client based on net asset value, invested capital,
the allocation of related time and services, or such other equitable basis as determined in the
discretion of Bridger. If Client account assets are invested in a master-feeder structure, the feeder
funds bear a pro rata share of the expenses associated with the related master fund.

The expenses incurred in connection with a transaction that is consummated will generally be
allocated among Funds and any participating third-party investors pro rata in accordance with their
respective actual investments or commitments in such investment opportunity, unless Bridger
determines that a different allocation methodology would be more equitable. Any expenses
incurred in connection with a transaction that is not consummated will generally be allocated
among the expected participants in the investment pro rata in accordance with their respective
expected investment or commitment in such unconsummated investment opportunity.

The Clients incur brokerage and other transaction costs when brokers are used in connection with
their investments. For additional information regarding brokerage practices, please see Item 12
below.
Account Minimums and Types of Clients — Form ADV Part 2A (3/27/2026) [Brochure]
Item 7: Types of Clients

Bridger provides investment advisory services to the Clients. Investment advice is provided
directly to the Funds, subject to the discretion and control of the general partner/managing member
or the board of directors of the applicable Fund, and not individually to the investors in the Funds.

Interests in the Funds are offered pursuant to applicable exemptions from registration under the
1940 Act and the Securities Act. Investors in the Funds may include high net worth individuals,
trusts, estates, charitable organizations, endowments, corporations, limited partnerships, limited
liability companies, pension funds, and similar entities.

With respect to a Client that is a pooled investment vehicle, any initial and additional subscription
minimums are disclosed in the Offering Documents for the pooled investment vehicle.

Bridger does not have any standard requirements for opening or maintaining a separately managed
account and may, in its discretion, require a different minimum for any Client account.
Sector Form 13F Holdings Value ($B)
Morgan Stanley 0.0
Amazon Com Inc 0.0
Teva Pharmaceutical Industries Ltd 0.0
Stars Group Inc 0.0
Dexcom Inc 0.0
Alcon Inc 0.0
Nike Inc 0.0
Alphabet Inc 0.0
Visa Inc 0.0
Churchill Downs Inc 0.0
View All
Holdings by Sector ($B)
4.03.22.41.60.80.02011201620212027
Type Form D Funds Date Sold AUM
PE Bridger Healthcare SIV I LP [2022-02-25] 17.5 M 1.4 M
Filed 2024-11-27 (D/A) · Exemption 506(b), 3(c), 3(c)(1) · Remaining Indefinite · Duration More than one year · Revenue Decline to Disclose
PE Bridger Healthcare SIV I LP 2021-11-29 17.5 M
HF Swiftcurrent Master Fund Ltd [2021-11-29] 1,371.3 M 297.6 M
Filed 2026-02-27 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose
HF Auson Holdings LLC [2018-10-08] 76.8 M 125.3 M
Filed 2025-07-11 (D/A) · Exemption 506(b), 3(c), 3(c)(1) · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose
HF Bridger Healthcare Ltd [2014-11-28] 235.0 M 0.3 M
Filed 2023-06-29 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration One year or less · Net Assets Decline to Disclose
HF Swiftcurrent Offshore Master Ltd [2014-03-31] 2,337.8 M 523.0 M
Filed 2026-02-27 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $100,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose
Other ALEA Partners LLC 2012-02-15 10.0 M
PE Bridger Horizon Vietnam Partners LP [2012-02-15] 1.1 M
Other North Forty Partners LLC 2012-02-15 28.9 M
HF Swiftcurrent Offshore Ltd [2012-02-15] 2,337.8 M 1,610.2 M
Filed 2026-02-27 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $100,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose
View All
AUM Breakdown Accounts AUM ($B)
By Client Type
(a) Individuals (other than high net worth individuals) 0 0.0
(b) Individuals (high net worth individuals) 0 0.0
(c) Banking or thrift institutions 0 0.0
(d) Investment companies 0 0.0
(e) Business development companies 0 0.0
(f) Pooled investment vehicles 3 0.5
(g) Pension and profit sharing plans 0 0.0
(h) Charitable organizations 0 0.0
(i) State or municipal government entities 0 0.0
(j) Other investment advisers 0 0.0
(k) Insurance companies 0 0.0
(l) Sovereign wealth funds and foreign official institutions 0 0.0
(m) Corporations or other businesses not listed above 0 0.0
(n) Other 0 0.0
Total 3 0.5
By Discretionary
Discretionary 3 0.5
Non-Discretionary 0 0.0
Total 3 0.5
By Non-United States Persons
Non-United States Persons 0.4
United States Persons 0.1
Total 3 0.5
Form D Directors Role # Filings # Firms 2011 - 2026
Robert Meschi Director 145 22
Brian Eden Director 36 15
Lucas Warford Executive Officer 8 3
Neil Cammarosano Director, Executive Officer 7 3
Bridger Management LLC Promoter 7 2
Roberto Mignone Executive Officer, Promoter 6 2
Michael Tierney Executive Officer 4 2
Blake Goodner Promoter 3 2
Matthew Truax Director, Executive Officer 3 1
Bridger Capital LLC Executive Officer 2 1
View All
EDGAR Form CIK 2011 - 2026
13F-HR [0001166309]
3 [0001166309]
4 [0001166309]
SC 13D [0001166309]
SC 13G [0001166309]
Form 13D/13G Filer Form 13D/13G Subject Filed
Bridger Management LLC Consonance-HFW Acquisition Corp [2020-11-30]
Bridger Management LLC Atara Biotherapeutics Inc [2019-11-01]
Bridger Management LLC TG Therapeutics Inc [2019-03-11]
Bridger Management LLC Dicerna Pharmaceuticals Inc [2018-06-21]
Bridger Management LLC Atara Biotherapeutics Inc [2017-04-21]
Bridger Management LLC Trovagene Inc [2016-11-15]
Bridger Management LLC Pacific Biosciences of California Inc [2016-04-25]
Bridger Management LLC Trovagene Inc [2016-04-05]
Bridger Management LLC Chimerix Inc [2016-01-19]
Bridger Management LLC TG Therapeutics Inc [2015-10-05]
Bridger Management LLC SeaSpine Holdings Corp [2015-07-20]
Bridger Management LLC Arrowhead Research Corp [2015-01-23]
Bridger Management LLC Medicines Co /DE [2014-10-20]
Bridger Management LLC Accuray Inc [2014-09-08]
Bridger Management LLC Tornier NV [2014-08-18]
Bridger Management LLC Channeladvisor Corp [2014-08-01]
Bridger Management LLC TG Therapeutics Inc [2014-01-31]
Bridger Management LLC Trovagene Inc [2013-08-09]
Bridger Management LLC Pennymac Financial Services Inc [2013-05-20]
Bridger Management LLC Wright Medical Group Inc [2012-10-26]
Bridger Management LLC Response Genetics Inc [2012-02-13]
Firm Profile (Form ADV)
Discretionary AUM$2.8B
ServesInstitutional
Fund TypesHedge Fund, Private Equity
LEIJM1U681K2Z42HG324E45
Form 3/4/5 Subject 2011 - 2026
Cardiff Oncology Inc
Bridger Management LLC
Mignone Roberto
Response Genetics Inc
Swiftcurrent Offshore Master Ltd
Swiftcurrent Offshore Ltd
Pennymac Financial Services Inc
Bridger Capital LLC
Swiftcurrent Partners LP
Insider Transaction (Form 3/4/5) Date Action Shares Price Value ($)
Cardiff Oncology Inc TROV
Common Stock, $.0001 par value per share
2016-11-11 Buy 322,472 $3.08 993,214
Response Genetics Inc RGDX
Common Stock, $0.01 par value per share
2015-11-18 Disposed to issuer 2,841,255 $0.00
Response Genetics Inc RGDX
Common Stock, $0.01 par value per share
2015-11-18 Disposed to issuer 1,793,745 $0.00
Response Genetics Inc RGDX
Common Stock, $0.01 par value per share
2015-11-17 Disposed to issuer 147,060 $0.00
Response Genetics Inc RGDX
Common Stock, $0.01 par value per share
2015-11-17 Disposed to issuer 232,940 $0.00
Response Genetics Inc RGDX
Common Stock, $0.01 par value per share
2015-11-16 Disposed to issuer 183,905 $0.00
Response Genetics Inc RGDX
Common Stock, $0.01 par value per share
2015-11-16 Disposed to issuer 116,095 $0.00
Response Genetics Inc RGDX
Common Stock, $0.01 par value per share
2015-11-13 Disposed to issuer 47,900 $0.00
Response Genetics Inc RGDX
Common Stock, $0.01 par value per share
2015-11-13 Disposed to issuer 547,100 $0.00
Response Genetics Inc RGDX
Common Stock, $0.01 par value per share
2015-11-11 Disposed to issuer 30,000 $0.00
Response Genetics Inc RGDX
Common Stock, $0.01 par value per share
2015-11-10 Disposed to issuer 60,000 $0.00
Cardiff Oncology Inc TROV
Common Stock, $0.0001 par value per share
2015-07-17 Buy 140,000 $8.75 1,225,000
Response Genetics Inc RGDX
Warrants (right to buy) · derivative
2015-04-03 Other 1,351,352
Cardiff Oncology Inc TROV
Common Stock, $.0001 par value per share
2015-04-02 Buy 300,000 $6.90 2,070,000
Cardiff Oncology Inc TROV
Common Stock, $.0001 par value per share
2015-02-27 Buy 79,343 $5.62 445,908
Cardiff Oncology Inc TROV
Common Stock, $.0001 par value per share
2015-02-26 Buy 78,801 $5.42 427,101
Cardiff Oncology Inc TROV
Common Stock, $.0001 par value per share
2015-02-25 Buy 105,142 $5.12 538,327
Cardiff Oncology Inc TROV
Common Stock, $.0001 par value per share
2015-02-06 Buy 444,444 $4.50 1,999,998
Response Genetics Inc RGDX
Common Stock, par value $.01 per share
2012-09-13 Buy 3,000,000 $1.10 3,300,000
Comparable Firms State AUM
Endowment Advisers LP
TX 499.7 M
Riposte Capital LLC
NY 496.6 M
Basin Oil and Gas Management LP
TX 492.7 M
OnyxPoint Global Management LP
NY 481.2 M
Lion Point Capital LP
NY 480.6 M
JW Asset Management LLC
476.9 M
Sycale Advisors NY LLC
NY 473.1 M
AOF Management LLC
CA 461.5 M
Saybrook Fund Advisors LLC
CA 461.2 M
Harspring Capital Management LLC
NY 459.1 M
Terms | Privacy | Providers | Companies | Guide
tony@aum13f.com